Expand EDIT Menu
EDIT MENU

EDIT Latest Press Releases

-- October 8, 2026 --

Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia Globe Newswire 7:00 AM

-- September 9, 2026 --

Editas Medicine Reports Inducement Grants to New Chief Medical Officer Globe Newswire 9:00 AM

-- September 8, 2026 --

Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer Globe Newswire 7:00 AM

-- September 1, 2026 --

Editas Medicine to Participate in Upcoming Investor Conferences Globe Newswire 9:00 AM

-- August 5, 2026 --

Editas Medicine Announces Second Quarter 2026 Results and Business Updates Globe Newswire 4:01 PM

-- August 4, 2026 --

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D. Globe Newswire 4:15 PM

-- May 28, 2026 --

Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference Globe Newswire 4:01 PM

-- May 26, 2026 --

Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering Globe Newswire 9:05 AM
Editas Medicine Announces Proposed Public Offering Globe Newswire 6:15 AM
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress Globe Newswire 6:01 AM

-- May 14, 2026 --

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting Globe Newswire 6:01 AM
Market Data Delayed 15 Minutes